Quick Order Cart

Cat. No. ARG43815

DDX3Y Knockout THP-1 Cell Line

  • Product Type:

    In Stock Cell Lines

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Blood (peripheral blood)

  • Disease:

    Acute monoblastic leukemia

The DDX3Y Knockout THP-1 Cell Line is a CRISPR/Cas9-edited human monocytic leukemia cell line lacking DDX3Y, a Y-chromosome DEAD-box helicase that enhances translation of cyclin D1 and c?Myc. THP-1 cells differentiate into macrophages upon PMA treatment, enabling studies of Y-chromosome gene function, sex-specific cancer differences, and translational control. DDX3Y interacts with DDX3X, eIF4E, and stress granule components, linking growth and stress pathways. This model supports Western blotting, RT?qPCR, cell cycle analysis, stress granule assays, and translation reporter studies, aiding research in leukemia, innate immunity, and RNA biology.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    THP-1

    Sex of Donor

    Male

    Age

    1 year

    Derived From Site

    In situ; Peripheral blood

    Gene Name

    DDX3Y

    Gene Identifier

    NCBI Gene ID 8653

    Growth Mode

    Suspension

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% COâ‚‚

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The DDX3Y Knockout THP-1 Cell Line is a CRISPR/Cas9-edited human monocytic leukemia cell line with disruption of the DDX3Y gene, providing a stable loss-of-function model. This product enables functional studies of the Y-chromosome-encoded DEAD-box RNA helicase DDX3Y in translational control, innate immunity, and cancer, and serves as a critical tool for exploring RNA helicase biology in leukemic and immune contexts.

The parental THP-1 cell line was established from the peripheral blood of a 1-year-old male with acute monocytic leukemia. THP-1 cells grow in suspension with a diameter of ~15 ??m and can be differentiated into macrophage-like cells upon treatment with phorbol 12-myristate 13-acetate (PMA). This cell line serves as a widely used model for monocyte and macrophage function, including cytokine signaling and phagocytosis, and is a relevant background for studying leukemogenesis and innate immune pathways.

DDX3Y encodes an ATP-dependent RNA helicase that unwinds secondary structures in the 5?? UTR of target mRNAs, including cyclin D1 (CCND1) and c?Myc (MYC), thereby stimulating cap-dependent translation initiation and cell proliferation. DDX3Y activity is regulated by androgen receptor, interferon-??/??/??, and stress stimuli such as oxidative stress. It interacts with DDX3X, exportin?1 (XPO1), eIF4E, PABP1, G3BP1, and TIA1 to control the expression of interferon-stimulated genes (ISGs), the cell cycle inhibitor p21, and stress granule components, thus linking proliferative and stress-responsive pathways.

Disruption of DDX3Y in the THP-1 background is predicted to impair cap-dependent translation of CCND1 and MYC, leading to reduced proliferation and cell cycle arrest. Because DDX3Y shares functional overlap with its X-linked paralog DDX3X, this knockout line enables dissection of Y-chromosome-specific functions, sex-dependent differences in cancer, and compensatory mechanisms. Additionally, the model can be used to investigate how loss of DDX3Y affects innate immune signaling, stress granule assembly, and macrophage differentiation, providing insights into leukemia and inflammation.

Applications include Western blotting for DDX3Y, cyclin D1, and c?Myc; RT?qPCR for DDX3Y and ISGs; proliferation and cell cycle assays; RNA immunoprecipitation; stress granule immunofluorescence; cap?dependent translation reporters; apoptosis detection; RNA?seq; and cytokine ELISA. For further details, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)